ZBIO Zenas BioPharma, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1953926 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-185.3%
TTM EPS YoY-173.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-265.1%
ROA-108.7%
ROIC (approx.)-441.5%
Asset turnover—
Leverage & solvency
Liabilities / assets68.6%
Debt / equity0.00x
Current ratio9.42x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.45x
Accruals ratio-60.0%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $10.00M | $5.00M |
| R&D expense | $168.06M | $139.14M |
| SG&A expense | $53.32M | $29.75M |
| Operating income | -$383.06M | -$163.89M |
| Interest expense | $7.33M | — |
| Pretax income | -$377.82M | -$156.56M |
| Income tax | -$79,000 | $429,000 |
| Net income | -$377.74M | -$156.99M |
| EBITDA | -$383.00M | -$163.75M |
| EPS (basic) | -8.44 | -11.89 |
| EPS (diluted) | -8.44 | -11.89 |
| Weighted avg. shares (diluted) | 44.73M | 13.20M |
| Balance sheet | ||
| Cash & equivalents | $110.64M | $319.83M |
| Short-term investments | $232.55M | $31.02M |
| Current assets | $351.17M | $355.92M |
| PP&E, net | $34,000 | $185,000 |
| Total assets | $383.64M | $369.97M |
| Current liabilities | $62.65M | $57.29M |
| Long-term debt | $78.64M | — |
| Total debt | $78.64M | — |
| Total liabilities | $141.50M | $57.51M |
| Shareholders' equity | $242.14M | $312.46M |
| Net debt | -$32.01M | — |
| Shares outstanding | 54.49M | 41.79M |
| Cash flow statement | ||
| Operating cash flow | -$172.33M | -$119.67M |
| Capital expenditure | $18,000 | $131,000 |
| Free cash flow | -$172.35M | -$119.81M |
| Investing cash flow | -$251.89M | -$30.55M |
| Financing cash flow | $215.28M | $412.96M |
| Depreciation & amortization | $56,000 | $137,000 |
| Stock-based compensation | $26.35M | $10.82M |
Free plan shows the latest 2 periods; Pro shows all 3 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.